Abstract：【Objective】To analyze the clinical application of nedaplatin combined with recombinant human vascular endostatin hyperthermia chemotherapy in the treatment of cancerous ascites. 【Methods】The clinical data of 60 patients with cancerous ascites admitted to our hospital from December 2015 to December 2018 were analyzed. They were divided into two groups with 30 cases each: the control group was treated with nedaplatin hyperthermia chemotherapy and the observation group was treated with nedaplatin combined with recombinant human vascular endostatin hyperthermia chemotherapy. The clinical efficacy of the two groups was analyzed before and after treatment. 【Results】In the observation group, there were 14 cases of complete remission and 13 cases of partial remission. Its total effective rate was 90.00%. In the control group, there were 6 cases of complete remission and 14 cases of partial remission. So, the total effective rate was 66.67%. The difference was statistically significant (χ2=4.812, P=0.028<0.05).There were no significant differences between the two groups in the levels of tumor markers CEA, glycoprotein antigen 19-9 (CA19-9) ,vascular endothelial growth factor (VEGF) and tumor necrosis factor alpha (TNF-α) before treatment (P>0.05). The levels of CEA, CA19-9,VEGF and TNF-α in the observation group were lower than those in the control group (P<0.05).The quality of life (Karnofsky score) in the observation group was 96.67% (29/30), which was significantly higher than that of the control group 73.33% (22/30). The difference was statistically significant (χ2=6.405,P=0.011<0.05). The adverse reactions of the two groups were all in grade Ⅰ~Ⅱ, and the occurrence of adverse reactions in the two groups was not statistically significant (P>0.05). 【Conclusion】Nedaplatin combined with recombinant human vascular endostatin thermal perfusion for the treatment of cancerous ascites has better clinical efficacy, which can reduce the levels of tumor markers, improve patients' quality of life without increasing adverse reactions.
黄汉生, 傅军民, 文建梅, 陈超庭, 杨小梅, 莫恰. 奈达铂联合重组人血管内皮抑制素热灌注治疗癌性腹水疗效观察[J]. 医学临床研究, 2019, 36(4): 696-698.
HUANG Han-sheng, FU Jun-min, WEN Jian-mei, et al. Clinical Study of Nedaplatin Combined with Recombinant Human Vascular Endostatin Hyperthermia Chemotherapy On the Treatment of Cancerous Ascites. JOURNAL OF CLINICAL RESEARCH, 2019, 36(4): 696-698.
2019, Vol. 36 
